Related Pages for LUPIN
LUPIN
Lupin LimitedNo results found.
LUPIN
2242.6
Related News - LUPIN
Lupin: Projects Effective Tax Rate For FY27 At 25% To 26% Because Of Reduced Incentives. US Revenue Expected To Exceed $1 Billion For FY27 Even With Some Competition-Related Decline. New Products And Business Growth May Help Mitigate Losses.
11 May 2026 08:56 AM
Lupin: Projects Effective Tax Rate For FY27 At 25% To 26% Because Of Reduced Incentives. US Revenue Expected To Exceed $1 Billion For FY27 Even With Some Competition-Related Decline. New Products And Business Growth May Help Mitigate Losses.
Lupin: Expects Strong Single-Digit Revenue Growth For Fiscal Year '27, Aiming For EBITDA Margins Of About 25%. This Margin Outlook Includes Expected Competition For Mirabegron And Tolvaptan And A Rise In R&D Spending.
11 May 2026 08:56 AM
Lupin: Expects Strong Single-Digit Revenue Growth For Fiscal Year '27, Aiming For EBITDA Margins Of About 25%. This Margin Outlook Includes Expected Competition For Mirabegron And Tolvaptan And A Rise In R&D Spending.
Lupin: Expects US Revenue To Remain Over $1 Billion In FY27, Anticipating A Possible High Single-Digit Or Low Double-Digit Revenue Drop Due To Competition For Tolvaptan And Mirabegron. Future Launches In FY28 Include Ranibizumab, Dulera, And A New Dosage Form Of Apixaban.
11 May 2026 08:56 AM
Lupin: Expects US Revenue To Remain Over $1 Billion In FY27, Anticipating A Possible High Single-Digit Or Low Double-Digit Revenue Drop Due To Competition For Tolvaptan And Mirabegron. Future Launches In FY28 Include Ranibizumab, Dulera, And A New Dosage Form Of Apixaban.
Lupin: Co Says Could See Negative Head Wind On Margins As Far As USA Is Concerned - CNBC
08 May 2026 12:17 PM
Lupin: Co Says Could See Negative Head Wind On Margins As Far As USA Is Concerned - CNBC
Lupin: Morgan Stanley maintains an Equal-weight on Lupin with a Target Price of ₹2386, as a strong Q4 beat across revenue, EBITDA and PAT was driven by robust US performance along with 11.5% YoY India growth and 49% YoY emerging market growth, aided by high-value gMyrbetriq and continued gSpiriva sales.
08 May 2026 08:53 AM
Lupin: Morgan Stanley maintains an Equal-weight on Lupin with a Target Price of ₹2386, as a strong Q4 beat across revenue, EBITDA and PAT was driven by robust US performance along with 11.5% YoY India growth and 49% YoY emerging market growth, aided by high-value gMyrbetriq and continued gSpiriva sales.
Lupin: Company Plans Over 20 Product Launches For FY27, Aiming To Outperform Market Growth; Also Targets 15+ ANDA Filings And Focus On Complex Generics And Biosimilars By 2028-2031.
07 May 2026 09:45 PM
Lupin: Company Plans Over 20 Product Launches For FY27, Aiming To Outperform Market Growth; Also Targets 15+ ANDA Filings And Focus On Complex Generics And Biosimilars By 2028-2031.
LUPIN: Q4 CONS NET PROFIT 14.6B RUPEES VS 7.73B (YOY) || Q4 REVENUE 74.7B RUPEES VS 56.7B (YOY)
07 May 2026 08:55 PM
LUPIN: Q4 CONS NET PROFIT 14.6B RUPEES VS 7.73B (YOY) || Q4 REVENUE 74.7B RUPEES VS 56.7B (YOY)
LUPIN: Q4 EBITDA 24.8B RUPEES VS 13.21B (YOY) || Q4 EBITDA MARGIN 33.6% VS 23.31% (YOY)
07 May 2026 08:55 PM
LUPIN: Q4 EBITDA 24.8B RUPEES VS 13.21B (YOY) || Q4 EBITDA MARGIN 33.6% VS 23.31% (YOY)
LUPIN: FINAL DIVIDEND 18 RUPEES PER SHARE
07 May 2026 08:55 PM
LUPIN: FINAL DIVIDEND 18 RUPEES PER SHARE
Lupin: Co-Launches Dapagliflozin And Metformin Extended-Release Tablets In The United States
22 Apr 2026 09:14 AM
Lupin: Co-Launches Dapagliflozin And Metformin Extended-Release Tablets In The United States
Lupin: USFDA Issues Form 483 With Three Observations For Its Somerset, New Jersey Manufacturing Site
18 Apr 2026 02:07 PM
Lupin: USFDA Issues Form 483 With Three Observations For Its Somerset, New Jersey Manufacturing Site
Lupin: Company Forms A New Thailand Subsidiary For International Growth
17 Apr 2026 05:23 PM
Lupin: Company Forms A New Thailand Subsidiary For International Growth
Lupin: Company Reaches Antitrust Settlement With Humana, Paying $30 Million; Lupin Denies All Claims
17 Apr 2026 07:33 AM
Lupin: Company Reaches Antitrust Settlement With Humana, Paying $30 Million; Lupin Denies All Claims
Lupin: Co Gets US Approval For Dapagliflozin Plus Metformin Hydrochloride Tablets
08 Apr 2026 05:28 PM
Lupin: Co Gets US Approval For Dapagliflozin Plus Metformin Hydrochloride Tablets
Lupin: Completes Visufarma B.V. Acquisition, Expanding Its Eye Care Portfolio To 60+ Branded Products And Strengthening Its Europe Presence.
02 Apr 2026 10:59 AM
Lupin: Completes Visufarma B.V. Acquisition, Expanding Its Eye Care Portfolio To 60+ Branded Products And Strengthening Its Europe Presence.
Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026
01 Apr 2026 07:02 PM
Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026
Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection
01 Apr 2026 08:33 AM
Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection
Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection
31 Mar 2026 01:16 PM
Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection
Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.
30 Mar 2026 09:42 AM
Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.
Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg
25 Mar 2026 06:04 PM
Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg
